secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001104659-24-028809
Event type: litigation
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance settles YUPELRI patent litigation with Lupin; generic launch delayed to April 23, 2039
--------------------------------------------------------------------------------

- Settlement grants Lupin a royalty-free, non-exclusive license to market generic revefenacin starting April 23, 2039.
- The settlement resolves ongoing Hatch-Waxman litigation based on Lupin's ANDA for YUPELRI.
- Patent litigation continues against three other ANDA filers: Cipla, Eugia Pharma, and Mankind Pharma.
- Settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924028809/0001104659-24-028809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924028809/tm247495d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-028809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer